Trending Topics in Gastroenterology | GastroAGI

Endoscopic versus surgical anti-reflux procedures for GERD

Endoscopic and surgical anti-reflux procedures are both effective treatment options for managing gastroesophageal reflux disease (GERD), but they differ significantly in terms of efficacy, safety, and patient suitability. Below is a detailed comparison based on the findings from the systematic review and network meta-analysis: ### 1. **Efficacy** - Both endoscopic and surgical interventions are more effective than continued proton pump inhibitor (PPI) therapy alone for controlling GERD symptoms and reducing the need for PPI use. - **Surgical Procedures**: - **Laparoscopic Nissen Fundoplication (LNF)**: Demonstrated the highest overall efficacy for reflux control and medication discontinuation (SUCRA = 0.84). It is considered the gold standard for GERD surgery. - **Laparoscopic Toupet Fundoplication (LTF)**: Ranked second in efficacy (SUCRA = 0.71). It is a partial fundoplication that may have fewer side effects compared to LNF. - **Anterior Partial Fundoplication (APF)**: Ranked third in efficacy (SUCRA = 0.70), offering a less invasive surgical option with good outcomes. - **Endoscopic Procedures**: - **Transoral Incisionless Fundoplication (TIF)**: While not as effective as surgical options for overall reflux control, TIF excelled in symptom relief, particularly for reducing heartburn (SUCRA = 0.87) and bloating (SUCRA = 0.86). ### 2. **Safety** - Surgical and endoscopic procedures generally have comparable safety profiles to continued PPI therapy. - **Surgical Procedures**: - LNF, while highly effective, is associated with a higher risk of postoperative complications such as dysphagia and gas-related symptoms. - **Endoscopic Procedures**: - TIF has the lowest rate of adverse effects among all evaluated procedures, making it a safer and less invasive alternative for patients who prioritize minimal side effects. ### 3. **Suitability** - **Surgical Procedures**: - Best suited for patients with severe GERD symptoms, significant anatomical abnormalities (e.g., large hiatal hernia), or those who require the strongest reflux control and long-term independence from medication. - However, patients must be aware of the potential for higher postoperative complications, particularly with LNF. - **Endoscopic Procedures**: - Ideal for patients who prefer a minimally invasive approach with fewer risks and are primarily seeking symptom relief (e.g., heartburn and bloating) rather than complete reflux control. - TIF, in particular, is a promising option for patients who are not candidates for surgery or who prioritize safety and quicker recovery. ### 4. **Patient Priorities** - Patients who prioritize long-term reflux control and independence from PPIs are better suited for surgical treatments like LNF. - Patients who prioritize safety, minimal invasiveness, and symptom relief without significant recovery time may prefer endoscopic treatments like TIF. ### Conclusion: Both endoscopic and surgical anti-reflux procedures are effective for GERD management, but the choice of treatment depends on individual patient needs, priorities, and risk tolerance. LNF provides the strongest reflux control and medication independence but carries a higher risk of complications. TIF, on the other hand, offers a safer, less invasive alternative with excellent symptom relief and minimal side effects, making it a promising option for selected patients. Consulting with a healthcare provider is essential to determine the most suitable approach based on the severity of GERD, anatomical considerations, and personal preferences.

Optimal timing for endoscopic treatment in patients with GERD

The optimal timing for endoscopic treatment in patients with gastroesophageal reflux disease (GERD) should be carefully individualized based on the patient's clinical profile, response to prior treatments, and overall health status. Endoscopic therapy is considered an intermediate option between pharmacological treatment (e.g., proton pump inhibitors, PPIs) and surgical intervention. Below are the key considerations for determining the optimal timing for endoscopic treatment: ### 1. **Failure of Proton Pump Inhibitor (PPI) Therapy** - **Primary Indication:** Endoscopic treatment is most appropriate for patients who have **refractory GERD**, meaning they experience persistent symptoms despite adequate PPI therapy. This includes incomplete relief of symptoms or continued issues such as regurgitation or atypical manifestations of GERD (e.g., chronic cough, laryngitis, or asthma). - **Relapse After PPI Discontinuation:** Patients who initially respond to PPIs but relapse after discontinuing the medication may also benefit from endoscopic therapy to reduce dependence on long-term pharmacological treatment. ### 2. **Patients Unwilling or Unable to Undergo Surgery** - **Surgical Alternatives:** While surgical options like fundoplication are effective for GERD, some patients may be unwilling to undergo invasive procedures or may have contraindications to surgery due to age, comorbidities, or other factors. Endoscopic therapy can serve as a less invasive alternative for these patients. - **Preference for Minimally Invasive Options:** Patients seeking a minimally invasive solution with shorter recovery times may opt for endoscopic treatment. ### 3. **Special Populations** - **Elderly Patients:** Older individuals, particularly those with multiple comorbidities, may not tolerate surgical intervention well. Endoscopic therapy can be considered earlier in such cases to improve quality of life while minimizing risks. - **Patients with Atypical or Extra-Esophageal GERD Symptoms:** Those with atypical symptoms (e.g., chest pain, chronic cough, or hoarseness) or extra-esophageal manifestations may benefit from endoscopic treatment if PPI therapy is insufficient. ### 4. **Symptom Burden and Quality of Life** - **Impact on Daily Life:** Patients whose GERD symptoms significantly impair their quality of life, despite medical therapy, may be candidates for endoscopic treatment. Timing should consider the severity of symptoms and their impact on daily functioning. ### 5. **Contraindications to Endoscopic Therapy** - Timing must also account for contraindications, such as anatomical abnormalities (e.g., large hiatal hernia), severe esophagitis, or esophageal motility disorders. These factors may necessitate alternative approaches like surgery. ### 6. **Individualized Decision-Making** - **Patient Selection:** Optimal timing requires a personalized approach, factoring in the patient's symptom profile, treatment history, and preferences. Shared decision-making between the patient and healthcare provider is critical. - **Biomarkers and Diagnostic Tools:** Future research may identify biomarkers or diagnostic criteria to better guide the timing of endoscopic intervention. ### 7. **Limitations and Evidence Gaps** - Current evidence lacks robust long-term outcome data and cost-effectiveness analyses for endoscopic therapies. As a result, timing decisions should be made cautiously, considering the patient's immediate needs and balancing the risks and benefits. ### Summary of Optimal Timing: Endoscopic treatment is optimally timed **after failure of PPI therapy** or in situations where patients cannot tolerate or prefer not to undergo surgery. It is particularly valuable for patients with refractory GERD, those with atypical manifestations, and special populations like the elderly or those with comorbidities. Timing decisions should be individualized and based on symptom severity, quality of life considerations, and contraindications to alternative therapies. Future research is needed to refine criteria for optimal timing and patient selection.

H. pylori infection in children and adolescents

Helicobacter pylori (H. pylori) infection in children and adolescents is a significant health concern due to its potential long-term impact on gastrointestinal health. This bacterial infection primarily affects the stomach lining and is associated with conditions such as gastritis, peptic ulcers, and, in severe cases, an increased risk of gastric cancer. Below is a detailed overview of the latest advancements in diagnosing and treating H. pylori infection in this age group: ### Diagnosis: 1. **Challenges in Pediatric Diagnosis**: - Diagnosing H. pylori in children is more complex than in adults due to differences in clinical presentation and the need for non-invasive testing methods. - Symptoms in children may include abdominal pain, nausea, vomiting, and poor appetite, but these are often non-specific. 2. **Emerging Molecular Diagnostic Methods**: - New molecular techniques are revolutionizing H. pylori detection and antimicrobial susceptibility testing. - These methods correlate strongly with traditional culture-based tests but are less reliant on factors like sample transport, timing, or laboratory expertise. - Molecular diagnostics are particularly useful for children with upper gastrointestinal bleeding and may soon expand to stool-based testing, offering a non-invasive alternative to endoscopy-based biopsy methods. - Stool antigen tests and urea breath tests are already widely used in children for non-invasive diagnosis. ### Treatment: 1. **Increasing Antimicrobial Resistance**: - Rising rates of antimicrobial resistance in pediatric H. pylori cases mirror adult trends, complicating treatment options. - Resistance to commonly used antibiotics like clarithromycin and metronidazole is a growing problem, necessitating tailored treatment strategies based on susceptibility testing. 2. **Updated Therapeutic Strategies**: - Optimized antibiotic regimens and acid suppression therapy are central to treatment. - Potassium-competitive acid blockers (PCABs), a newer class of acid-suppressive drugs, are being introduced. These drugs provide superior acid control compared to traditional proton pump inhibitors (PPIs) and may improve eradication rates. - Triple therapy (antibiotics + acid suppression) and quadruple therapy (antibiotics + bismuth + acid suppression) remain the standard approaches, but treatment regimens are increasingly individualized based on resistance profiles. 3. **Eradication Benefits**: - Successful eradication of H. pylori in children is critical for preventing complications like peptic ulcers and reducing the risk of gastric cancer later in life. - Large-scale studies in adults have shown that eradication lowers gastric cancer risk, and pediatric research is beginning to document the progression of premalignant gastric lesions. ### Innovations and Future Directions: 1. **Non-Invasive Testing**: - The development of stool-based molecular diagnostic tests could transform how H. pylori is detected in children, offering a painless and convenient alternative to invasive procedures like endoscopy. 2. **Personalized Medicine**: - Advances in molecular diagnostics are paving the way for more tailored treatment approaches. By identifying specific antibiotic resistance patterns, clinicians can select the most effective therapy for each child, minimizing the need for repeated empirical treatments. 3. **Guideline Updates**: - While official pediatric guidelines are still awaited, emerging data and innovations in diagnostics and treatment are expected to shape future recommendations for managing H. pylori infection in children. ### Conclusion: H. pylori infection in children and adolescents presents unique challenges in diagnosis and treatment, but recent advancements in molecular diagnostic techniques and acid-suppressive therapies offer promising solutions. These innovations aim to improve eradication rates, reduce antimicrobial resistance issues, and provide individualized care. As research continues, the focus remains on minimizing the long-term health risks associated with H. pylori infection in the pediatric population.

H.Pylor related chronic atrophic gastritis and Gastric Cancer

Helicobacter pylori (H. pylori)-related chronic atrophic gastritis (CAG) is a condition where long-term infection by H. pylori bacteria leads to damage in the stomach lining. This damage includes inflammation, loss of stomach gland cells (atrophy), and replacement of normal stomach tissue with intestinal-like cells, known as intestinal metaplasia (IM). CAG caused by H. pylori significantly increases the risk of developing gastric cancer. H. pylori is classified as a Class I carcinogen due to its strong link to stomach cancer. The bacteria release harmful proteins, such as CagA and VacA, which disrupt normal cell functions, trigger chronic inflammation, and cause DNA damage. This persistent inflammation accelerates the progression of Correa’s cascade, a step-by-step process from gastritis to IM, dysplasia (abnormal cell growth), and eventually gastric cancer. Additionally, H. pylori can evade the immune system, allowing the infection to persist and promote cancer development. Epigenetic changes, such as DNA methylation, play a major role in this process. H. pylori silences tumor-suppressor genes and activates cancer-promoting pathways like WNT and NF-κB. Co-infection with Epstein–Barr virus (EBV) further increases cancer risk through combined effects on cellular growth and signaling. While early eradication of H. pylori can prevent progression, advanced stages of IM or dysplasia may become irreversible. Treatment typically involves antibiotics combined with proton pump inhibitors, with newer therapies like vonoprazan showing promise. Regular monitoring after eradication is essential, as early detection and intervention can significantly reduce the risk of gastric cancer.

Gut microbiome mediates the associations between lifestyle factors and colorectal high-risk adenoma

The study you are referencing provides compelling evidence that the gut microbiome acts as a mediator in the relationship between lifestyle factors—such as obesity, smoking, and alcohol consumption—and the development of colorectal high-risk adenomas (HRAs). To address your query comprehensively, let's explore the concepts of the gut microbiome, high-risk colorectal adenomas, and how lifestyle factors and the gut microbiome influence the risk of developing HRAs. ### What is the Gut Microbiome? The gut microbiome refers to the community of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside in the gastrointestinal tract. These microbes play crucial roles in digestion, immune system modulation, nutrient absorption, and maintaining overall gut health. Importantly, the gut microbiome can influence systemic inflammation, immune responses, and even the development of diseases, including colorectal cancer (CRC). ### What are High-Risk Colorectal Adenomas (HRAs)? High-risk colorectal adenomas (HRAs) are precancerous lesions found in the colon or rectum. They are advanced adenomas with significant malignant potential, meaning they are more likely to progress into colorectal cancer (CRC) if left untreated. HRAs are characterized by features such as large size (>10 mm), villous histology, or high-grade dysplasia. Identifying and understanding the risk factors for HRAs is critical for early prevention of CRC. ### How Lifestyle Factors Influence HRA Development The study identified three key lifestyle factors—obesity, smoking, and alcohol consumption—that independently increase the risk of developing HRAs. Here's how each factor contributes: 1. **Obesity**: Elevated body mass index (BMI) was found to increase the risk of HRAs, with an odds ratio (OR) of 1.06 per kg/m². Obesity is linked to chronic low-grade inflammation, insulin resistance, and altered hormone levels, all of which can promote colorectal neoplasia. Additionally, obesity alters gut microbiota composition, potentially amplifying inflammation and carcinogenesis. 2. **Smoking**: Heavy cigarette smoking (>30 pack-years) increased HRA risk by 44%. Tobacco exposure introduces carcinogenic compounds into the body, which can directly damage DNA and promote inflammation. Smoking also reshapes the gut flora, favoring pro-inflammatory microbial taxa such as Tyzzerella 4 and Actinomyces, which are implicated in colorectal tumorigenesis. 3. **Alcohol Consumption**: High alcohol intake (>4 units per week) was associated with a 65% increase in HRA risk. Alcohol metabolism generates acetaldehyde, a known carcinogen, which can damage DNA and impair mucosal barriers in the gut. Alcohol also influences gut microbiota composition, enriching harmful taxa like Fusobacterium while depleting beneficial bacteria such as Bifidobacterium. ### How the Gut Microbiome Mediates Lifestyle-Driven HRA Risk The study revealed that lifestyle factors alter the gut microbiome, and these microbial changes mediate the carcinogenic effects of obesity, smoking, and alcohol consumption. Key findings include: 1. **Microbiome Diversity**: Gut microbiota diversity (β-diversity) varied significantly across groups based on BMI, smoking, and alcohol consumption. This indicates that lifestyle factors disrupt microbial composition, potentially creating a pro-inflammatory and tumor-promoting environment. 2. **Key Microbial Genera**: - **Fusobacterium**: Alcohol consumption was positively correlated with Fusobacterium, which was significantly enriched in HRA patients. Fusobacterium is known to promote chronic inflammation, immune suppression, and mucosal barrier dysfunction, all of which accelerate neoplastic transformation. - **Tyzzerella 4**: Smoking intensity was linked to an increase in Tyzzerella 4, another pro-inflammatory genus enriched in HRA patients. Tyzzerella 4 completely mediated 14.2% of the effect of smoking on HRA risk, highlighting its role in tumor-promoting inflammation. - Beneficial genera such as Faecalibacterium, Lachnospira, and Parasutterella were depleted in HRA patients, suggesting a loss of anti-inflammatory and gut-protective microbes. 3. **Sex-Specific Findings**: Mediation by Fusobacterium and Tyzzerella 4 was observed only in male participants, suggesting that sex-dependent differences in microbial composition and immune responses play a role in HRA development. ### Mechanistic Insights The study provided mechanistic insights into how Fusobacterium and Tyzzerella 4 contribute to HRA risk: - **Chronic Inflammation**: Both genera are implicated in promoting inflammation, which is a key driver of colorectal tumorigenesis. - **Immune Suppression**: These microbes can suppress immune surveillance, allowing precancerous lesions to progress. - **Mucosal Barrier Dysfunction**: Fusobacterium and Tyzzerella 4 can disrupt the gut's protective mucosal barrier, increasing susceptibility to carcinogens. ### Preventive Implications The findings suggest that modifying gut microbiota composition could lower HRA risk. Potential interventions include: - **Probiotics**: Introducing beneficial bacteria to counteract harmful taxa. - **Dietary Changes**: Consuming a high-fiber, low-fat diet to promote gut health and microbial diversity. - **Lifestyle Modifications**: Reducing alcohol consumption, quitting smoking, and maintaining a healthy weight to prevent microbial shifts associated with HRAs. ### Study Limitations While the study provides valuable insights, it has limitations: - **Retrospective Design**: The study relied on self-reported lifestyle data, which may be subject to recall bias. - **16S rRNA Sequencing**: This method provides genus-level resolution but cannot identify species-level microbial changes. - **Population Specificity**: The cohort was limited to East Asian populations, which may constrain generalizability to other ethnic groups. ### Conclusion The study underscores the critical role of the gut microbiome in mediating the effects of lifestyle factors on colorectal high-risk adenomas. Specifically, Fusobacterium and Tyzzerella 4 emerge as microbial links between alcohol and smoking exposure and HRA risk. These findings highlight the potential of gut microbiome-targeted interventions—such as probiotics, dietary changes, and lifestyle modifications—for early prevention of colorectal cancer.

Eosinophilic esophagitis and food allergies: A US National Analysis

Eosinophilic Esophagitis (EoE) and food allergies are closely intertwined. A recent US national analysis, leveraging data between 2016 and 2022, provides critical insights into the relationship between EoE and IgE-mediated food allergies such as milk, egg, peanut, and seafood allergies. Here is a detailed breakdown of the findings: ### **Study Objective** The study aimed to evaluate the association between EoE and specific food allergies using a large inpatient dataset. EoE is a chronic, immune-mediated esophageal disease driven by eosinophil inflammation, often triggered by food antigens. However, the exact relationship between specific food allergies and EoE had not been fully quantified prior to this study. ### **Study Design and Dataset** - **Design**: Retrospective cross-sectional analysis. - **Dataset**: National Inpatient Sample (NIS), the largest publicly available all-payer inpatient database in the US. - **Study Period**: 2016–2022. - **Population**: Included all US hospitalizations with a diagnosis of EoE (ICD-10 code K20.0) and comorbid food allergies (milk, egg, peanut, seafood). ### **Key Findings** #### **Sample Size** - Out of 46,575 EoE hospitalizations: - **Milk allergy**: 1,765 cases (3.79%) - **Egg allergy**: 1,535 cases (3.30%) - **Peanut allergy**: 1,460 cases (3.13%) - **Seafood allergy**: 1,185 cases (2.54%) #### **Demographics** - **Age**: Mean age of EoE patients was 36.4 years. However, patients with food allergies were significantly younger: - Milk, egg, and peanut allergy cases: Around 13–15 years. - Seafood allergy cases: Around 22 years. - **Sex Distribution**: Males constituted the majority of EoE cases (65–68%), confirming a strong male predominance. - **Racial Disparities**: White patients had the highest rates of EoE. Black and Hispanic patients had lower odds of EoE (adjusted odds ratio [aOR] of 0.47 and 0.45, respectively), suggesting potential disparities in diagnosis or healthcare access. #### **Socioeconomic and Insurance Trends** - **Income**: Patients from the highest household income quartile (≥$86,000) had increased odds of EoE (aOR 1.79), indicating differences in healthcare access and diagnosis. - **Insurance**: Privately insured (aOR 3.09) and Medicaid-covered (aOR 2.34) patients had higher odds of EoE compared to Medicare patients, possibly due to differences in healthcare utilization and referral pathways. #### **Geographic Trends** - The highest proportion of EoE cases with food allergies was reported in the South (35–41%), followed by the Midwest and Northeast. This may reflect regional diagnostic or environmental influences. #### **Hospital Characteristics** - Most EoE admissions occurred in large metropolitan hospitals (over 60%), suggesting better access to diagnostic procedures like endoscopy in high-volume centers. #### **Age-Related Trends** - **Pediatric patients (<18 years)**: Had the highest likelihood of EoE. - **Adults aged 45–64 and ≥65 years**: Had significantly reduced odds of EoE (aOR 0.18 and 0.06, respectively). #### **Food Allergy-Specific Associations** - Logistic regression revealed strong associations between EoE and specific food allergies: - **Milk allergy**: Strongest association (aOR 7.52, p<0.001). - **Egg allergy**: aOR 4.77. - **Peanut allergy**: aOR 3.94. - **Seafood allergy**: aOR 2.57. #### **Temporal Trends** - Between 2016 and 2022, EoE-related hospitalizations increased significantly (from 5,620 to 7,664 cases). However, the relative proportions of specific food allergies remained stable. #### **Sex-Specific Findings** - Female patients with food allergies had lower odds of EoE (aOR 0.52, p<0.001), reinforcing the male predominance in EoE prevalence. #### **Comorbidity Impact** - EoE patients with fewer comorbidities (Charlson Comorbidity Index = 1) were more likely to have food allergy-related EoE (aOR 1.58), suggesting that EoE often occurs in otherwise healthy individuals. #### **Clinical Insights** - **Milk Allergy**: Milk allergy’s strong association with EoE supports the "cow’s milk hypothesis," where milk proteins are a predominant trigger for EoE. This validates dietary elimination approaches like the one-food elimination diet (1FED). - **Screening Importance**: Early screening for EoE in children with known food allergies, particularly males and those with milk sensitivity, is crucial to prevent chronic inflammation and fibrosis. ### **Clinical Implications** 1. **Tailored Dietary Management**: The study highlights the need for personalized dietary interventions for EoE patients with food allergies, especially milk sensitivity. 2. **Early Detection**: Screening high-risk groups—children, males, and those with milk allergy—can prevent long-term complications like esophageal fibrosis. 3. **Equitable Access**: Addressing racial and socioeconomic disparities in diagnosis and management is essential for improving patient outcomes. 4. **Regional Focus**: Understanding geographic trends can help allocate resources to regions with higher EoE prevalence. ### **Conclusions** This national analysis demonstrates a strong, statistically significant link between EoE and specific food allergies—especially milk, egg, peanut, and seafood. The findings emphasize the importance of early diagnosis, tailored dietary management, and equitable healthcare access to improve outcomes for EoE patients. Milk allergy, in particular, stands out as a predominant trigger, validating dietary elimination strategies and underscoring the need for focused clinical interventions.

FLIP panometry

FLIP panometry, or Functional Lumen Imaging Probe panometry, is a diagnostic tool used during endoscopy to assess the esophagogastric junction (EGJ) opening and esophageal contractile activity. It complements traditional motility testing by providing additional information about esophageal function. Despite its growing use, variability in procedures and interpretations has caused inconsistencies in clinical practice. To address this, the Dallas Consensus was developed by 19 international experts using a structured Delphi process. Through three rounds of voting and discussions, the group created standardized guidelines for performing and interpreting FLIP panometry. They finalized 40 statements covering procedural techniques, data interpretation, and motility classification systems. These guidelines aim to ensure uniformity and reliability in clinical use worldwide. FLIP results should always be interpreted alongside clinical presentation, endoscopic findings, and complementary motility studies for accurate diagnosis. A "normal" FLIP panometry strongly indicates the absence of major motor disorders, providing reassurance in diagnosis. Additionally, diminished or absent contractile responses combined with reduced EGJ opening can identify EGJ outflow obstruction, supporting the diagnosis of related disorders. The Dallas Consensus introduced an updated motility classification system, aligning FLIP interpretations with high-resolution manometry and improving clinical outcomes. By standardizing procedures and interpretive criteria, the consensus enhances the reliability and broader application of FLIP panometry in diagnosing esophageal motility disorders. This tool is now better equipped to help clinicians evaluate and manage conditions affecting esophageal function.

Familial Eosinophilic Esophagitis

Familial Eosinophilic Esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus with a strong genetic basis. Research has shown that EoE often clusters within families, suggesting genetic predisposition plays a significant role. A recent study aimed to uncover specific genes linked to familial EoE by using two advanced techniques: whole exome sequencing (to analyze rare genetic variants) and RNA sequencing (to study gene expression). The study analyzed 50 familial EoE cases from 21 extended families using exome sequencing and 43 cases from 18 nuclear families using RNA sequencing. Exome sequencing identified 189 rare genetic variants across 181 genes shared among affected family members. RNA sequencing revealed 698 genes with altered expression in EoE cases compared to healthy controls, indicating widespread changes in gene activity linked to the disease. Three genes—MUC16, ADGRE1, and TENM3—stood out as strong candidates for EoE susceptibility. These genes not only carried rare variants shared by affected relatives but also showed abnormal expression patterns. Additionally, 36 other genes demonstrated partial variant sharing and differential expression, suggesting a complex polygenic nature of EoE. Interestingly, some EoE-related genes were abnormally expressed in unaffected family members, hinting at a latent genetic predisposition or subclinical molecular changes. Many identified genes are involved in immune regulation, epithelial barrier function, and cell adhesion, processes central to EoE development. This study supports a "multihit" model for familial EoE, where inherited genetic vulnerabilities interact with environmental or immune triggers to cause the disease. These findings offer insights into the genetic and molecular mechanisms underlying EoE and may guide future research and treatments.

AGES-D Score and GERD

The AGES-D score is a diagnostic tool developed to predict gastroesophageal reflux disease (GERD) with moderate-to-high accuracy by integrating demographic and high-resolution manometric (HRM) parameters. It was specifically designed to assist clinicians in evaluating patients with inconclusive reflux monitoring results, particularly when esophageal acid exposure time (AET) falls within the indeterminate range of 4–6%. ### Key Features of the AGES-D Score: 1. **Purpose**: - The AGES-D score aims to provide a structured, quantitative approach to diagnosing GERD in patients with ambiguous pH monitoring results. It is particularly useful in cases where traditional diagnostic methods fail to yield conclusive results. 2. **Parameters Used**: The AGES-D score is based on five independent predictors of GERD, which form the acronym "AGES-D": - **A**ge: Older age is associated with a higher likelihood of GERD. - **G**ender: Male sex is a significant risk factor for GERD. - **E**GJ (Esophagogastric Junction) Contractile Integral (EGJ-CI): Lower EGJ-CI values are indicative of a weakened anti-reflux barrier. - **S** LES–Crural Diaphragm Distance (LES-CD): A larger LES-CD distance suggests a greater separation between the lower esophageal sphincter (LES) and the diaphragmatic crura, often associated with hiatal hernia and GERD. - **D**istal Contractile Integral (DCI): Lower DCI values indicate impaired esophageal peristaltic function, which compromises acid clearance and increases the risk of reflux. 3. **Calculation**: The AGES-D score is calculated using the following logistic regression equation: ``` AGES-D score = -0.6162 + (0.0222 × age) + (0.5917 if male) + (0.02298 × LES-CD) – (0.01771 × EGJ-CI) – (0.00037183 × DCI) ``` - A cutoff score of **≥0.125** provides 73% sensitivity and 75% specificity for diagnosing GERD. 4. **Validation**: - The AGES-D score was validated using a cohort of 391 adult patients with GERD symptoms who underwent 24-hour pH or pH-impedance monitoring and HRM. - In the derivation cohort (n=261), the score achieved an area under the curve (AUC) of 0.76, and in the validation cohort (n=130), it achieved an AUC of 0.82, demonstrating strong reproducibility and diagnostic accuracy. 5. **Clinical Utility**: - The AGES-D score is particularly valuable for patients with inconclusive pH or impedance monitoring results (AET 4–6%), where traditional diagnostic methods cannot definitively confirm or rule out GERD. - It provides a practical and cost-effective tool that incorporates both demographic and manometric data to improve diagnostic certainty without requiring subjective maneuvers or additional impedance-based variables. 6. **Advantages Over Existing Scores**: - The AGES-D score is simpler than other diagnostic systems like the Milan, COuGH RefluX, and Lyon scores. - It relies solely on objective and routinely available HRM parameters, avoiding subjective measures such as symptom scoring or complex maneuvers like leg-raising. 7. **Limitations**: - The study was retrospective and conducted at a single center, which may limit the generalizability of the findings. - The tool has not yet been validated in prospective multicenter studies or across diverse ethnic populations. - The study excluded patients with indeterminate AET values (4–6%), which is the population for whom the score is ultimately intended, potentially introducing a selection bias. 8. **Future Research**: - Prospective multicenter studies are needed to externally validate the AGES-D score. - Research should also assess the score’s predictive value for treatment response and compare it directly with established reflux diagnostic models. ### Clinical Implications: The AGES-D score represents a significant advancement in the diagnostic workup of GERD, particularly for cases where traditional reflux testing is inconclusive. By combining demographic factors (age and gender) with HRM metrics (EGJ-CI, LES-CD, and DCI), the score provides a comprehensive assessment of both structural and functional aspects of the esophagus. This makes it a valuable adjunct to traditional reflux testing, helping clinicians make more informed treatment decisions. In summary, the AGES-D score is a robust, evidence-based tool that enhances GERD diagnosis by integrating easily obtainable parameters. While promising, further validation in diverse populations and clinical settings is necessary to confirm its utility and reliability in routine practice.

pH-integrated ultrathin endoscopy for ambulatory GERD monitoring

The pH-integrated ultrathin endoscopy, known as the EndoMonitor System, represents a groundbreaking innovation for ambulatory gastroesophageal reflux disease (GERD) monitoring. This newly developed device integrates real-time pH measurement with direct video imaging of reflux episodes, addressing limitations of traditional pH-impedance catheters, such as subjective interpretation, delayed analysis, and lack of visual correlation with reflux events. The EndoMonitor is a 2.8 mm ultrathin transnasal endoscope equipped with an antimony pH electrode and a miniature CMOS camera. It connects to mobile devices for live visualization, allowing simultaneous recording of pH changes and reflux events. Preclinical evaluation included in vitro (porcine esophagus-stomach models) and in vivo (miniature pig) experiments, demonstrating superior detection accuracy compared to conventional pH-impedance catheters. The EndoMonitor achieved 100% detection of distal acid, distal mixed, and horizontal acid reflux, outperforming the catheters, which showed significantly lower detection rates. Additionally, it accurately identified proximal reflux events with over 90% accuracy. The device offers real-time visualization of reflux episodes and pH drops, enabling objective identification of reflux type, height, duration, and composition (acidic vs. mixed) without the need for post-hoc analysis. It also provides insights into esophageal motility and clearance through documentation of post-reflux swallow-induced peristaltic waves (PSPW), critical for assessing reflux burden and mucosal protection. The safety profile was excellent, with no device malfunctions or adverse effects observed during prolonged monitoring. While preclinical limitations exist, such as the absence of symptomatic human subjects, planned clinical trials aim to validate the EndoMonitor in conscious humans for long-term use. This dual-mode system offers the potential to redefine GERD diagnostics by combining physiologic data and anatomical imaging, setting a new standard for real-time, visualized reflux assessment.